Abstracts tagged "biologic response modifiers and rheumatoid arthritis (RA)"

Abstract Number: 1841 • 2012 ACR/ARHP Annual Meeting
Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
Denis Choquette¹, Oliver Thomas² and Mark Arundine², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Roche, Toronto, ON, Canada
Background/Purpose: Reports suggest that a large proportion of patients who acquire and use biologic DMARD agents (biologics) to treat Rheumatoid Arthritis (RA) do not acquire…
Abstract Number: 1332 • 2012 ACR/ARHP Annual Meeting
The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA
Tamao Nakashita¹, Shinji Motojima², Natsuki Fujio² and Akira Jibatake³, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Exacerbation of interstitial lung disease (ILD) is a problem when biologics are administrated in patients with RA, and not a few fatal cases have…
Abstract Number: 1246 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Rheumatoid Arthritis (RA) Patients Treated by Biologic Response Modifiers
Majed M. Khraishi¹, Rana Aslanov² and Katie Doyle¹, ¹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada
Background/Purpose: We aimed to assess the 10-year CV event risk in patients with RA at the baseline and 1 year after the initiation of treatment…
Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting
Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Denis Choquette¹, Diane Sauvageau², Boulos Haraoui² and Jean-Pierre Raynauld², ¹Rheumatology, Institut de Rhumatologie De Montréal, Montreal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].